Athira Pharma Shares Jump 70% On Phase 3 Asset Acquisition Deal

Core Viewpoint - Athira Pharma, Inc. announced an agreement to acquire global development and commercialization rights to lasofoxifene, a Phase 3 ready asset for metastatic breast cancer, leading to a significant surge in its stock price [1] Group 1: Stock Performance - Athira Pharma shares surged 69.53 percent, gaining $2.88 to trade at $7.01 on Thursday [1] - The stock opened at $7.22 and fluctuated within a day's range of $6.77 to $8.35 [2] - Trading volume spiked to approximately 53.19 million shares, significantly higher than the average volume of around 30,063 shares [2] Group 2: Market Reaction - Investors reacted positively to the late-stage pipeline expansion, with shares now trading near the top of its 52-week range of $2.20 to $8.35 [2]